Performance Overview - Revenue for 2Q2025 reached RMB 3,342 million, a 7.9% increase QoQ and a 13.9% increase YoY [14] - Net profit for 2Q2025 was RMB 396 million, reflecting a 29.5% increase QoQ but a 55.2% decrease YoY due to prior investment income [14] - Non-IFRS net profit for 2Q2025 was RMB 406 million, showing a 16.3% increase QoQ and a 15.6% increase YoY [14] Financial Highlights - Total revenue for 1H2025 was RMB 6,441 million, a 14.9% increase YoY [15] - Net profit for 1H2025 was RMB 701 million, down 37.0% YoY [15] - Non-IFRS net profit for 1H2025 was RMB 756 million, a 9.5% increase YoY [15] Customer and Market Insights - New purchase orders (POs) increased by over 10% YoY [15] - Revenue from the top 20 global pharmaceutical companies increased by 48.0% YoY [15] - Active customer base includes over 2,600 customers, with 480+ new customers added [16] Revenue Composition - Revenue from China entities accounted for 88%, while overseas subsidiaries contributed 12% [19] - Laboratory services made up 60% of total revenue, followed by small molecule CDMO services at 22% and clinical development services at 15% [19] Global Presence and Projects - The company is involved in 795 drug discovery projects and 1,027 clinical CRO projects, including 89 in Phase III [17] - The company operates 21 R&D and manufacturing facilities across China, the UK, and the US [16] Future Outlook - The company expects to maintain a full-year 2025 revenue growth guidance of 10-15% [15] - Anticipated recovery in demand from Chinese customers, alongside sustained global customer demand [54]